• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.

作者信息

Conticini Edoardo, Bargagli Elena, Bardelli Marco, Rana Giuseppe Domenico, Baldi Caterina, Cameli Paolo, Gentileschi Stefano, Bennett David, Falsetti Paolo, Lanzarone Nicola, Bellisai Francesca, Barreca Cristiana, D'Alessandro Roberto, Cantarini Luca, Frediani Bruno

机构信息

Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy

Department of Medicine, Surgery and Neurosciences, Pneumology Unit, University of Siena, Siena, Italy.

出版信息

Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15.

DOI:10.1136/annrheumdis-2020-217681
PMID:32414804
Abstract
摘要

相似文献

1
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.一大群接受生物和靶向合成抗风湿药物治疗的患者中的新冠肺炎肺炎
Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15.
2
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini .风湿性疾病患者中新型冠状病毒肺炎（COVID-19）的患病率：需要等待大型合作研究的结果。对Conticini所著《一大群接受生物和靶向合成抗风湿药物治疗的患者中的COVID-19肺炎》的回应
Ann Rheum Dis. 2021 Feb;80(2):e15. doi: 10.1136/annrheumdis-2020-217738. Epub 2020 May 15.
3
A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy.非肿瘤坏死因子抑制剂和靶向合成药物在妊娠期风湿性疾病中安全性的系统评价。
Clin Med (Lond). 2020 Mar;20(Suppl 2):s98. doi: 10.7861/clinmed.20-2-s98.
4
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
5
Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs.使用生物药物治疗的风湿性疾病儿童感染新冠病毒后无严重并发症
J Rheumatol. 2021 Aug;48(8):1343-1344. doi: 10.3899/jrheum.200483. Epub 2020 Apr 25.
6
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.使用靶向合成或生物改善病情抗风湿药物或甲氨蝶呤治疗的风湿性疾病患者中新冠病毒病的患病率、入院率及缺氧情况：冰岛的一项全国性研究
Ann Rheum Dis. 2021 May;80(5):671-672. doi: 10.1136/annrheumdis-2020-219564. Epub 2021 Jan 5.
7
Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study.接受生物性改善病情抗风湿药物治疗的炎症性风湿病患者中新冠病毒病的发生率和严重程度：一项横断面研究
Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1273. Epub 2020 Nov 22.
8
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops .对舒尔茨 - 库普斯所著的《接受利妥昔单抗治疗的炎症性风湿病患者发生重症 COVID-19 的风险增加》的回应 。
Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26.
9
Who Needs a Corona?谁需要新冠病毒？
Arthritis Rheumatol. 2020 Jun;72(6):874-876. doi: 10.1002/art.41260. Epub 2020 Apr 20.
10
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.慢性炎症和自身免疫性风湿病患者中经医院聚合酶链反应（PCR）确诊的 COVID-19 病例的流行情况。
Ann Rheum Dis. 2020 Sep;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763. Epub 2020 Jun 12.

引用本文的文献

1
Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran.在伊朗大流行的第一波和第二波期间，生物制剂和传统改善病情抗风湿药物对风湿病患者中新冠病毒感染发病率的影响。
Reumatologia. 2022;60(4):231-241. doi: 10.5114/reum.2022.119039. Epub 2022 Sep 7.
2
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar.卡塔尔自身免疫性风湿病多民族患者队列中2019冠状病毒病的患病率
Qatar Med J. 2022 Aug 5;2022(3):37. doi: 10.5339/qmj.2022.37. eCollection 2022.
3
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.
葡萄牙炎症性风湿病患者感染的危险因素、重症疾病预测因素及对 COVID-19 的抗体反应——一项多中心全国性研究
Front Med (Lausanne). 2022 Jun 13;9:901817. doi: 10.3389/fmed.2022.901817. eCollection 2022.
4
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians.SARS-CoV-2 大流行背景下慢性呼吸道疾病患者的风险评估：德国呼吸学会与德国胸科医师协会支持的立场声明。
Respiration. 2022;101(3):307-320. doi: 10.1159/000518896. Epub 2022 Jan 21.
5
Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.COVID-19 大流行对多发性硬化症转诊中心临床就诊频率、MRI 研究开展情况和治疗选择的影响。
J Neurol. 2022 Apr;269(4):1764-1772. doi: 10.1007/s00415-021-10958-z. Epub 2022 Jan 10.
6
SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center.风湿性疾病患儿的新型冠状病毒2型感染：一家三级转诊中心的经验
Arch Rheumatol. 2021 Feb 9;36(3):381-388. doi: 10.46497/ArchRheumatol.2021.8603. eCollection 2021 Sep.
7
Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran.白塞病患者中的2019冠状病毒病：伊朗59例报告
Clin Rheumatol. 2022 Apr;41(4):1177-1183. doi: 10.1007/s10067-021-06004-y. Epub 2021 Nov 29.
8
A review of the presentation and outcome of sarcoidosis in coronavirus disease 2019.2019冠状病毒病中结节病的临床表现与转归综述。
J Clin Transl Res. 2021 Sep 27;7(5):657-665. eCollection 2021 Oct 26.
9
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.类风湿关节炎的生物疗法：临床医生概述
Biologics. 2021 Aug 12;15:343-352. doi: 10.2147/BTT.S252575. eCollection 2021.
10
Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients.既往免疫抑制治疗与 COVID-19 患者的死亡率相关：一项对 835 例患者的回顾性研究。
J Med Virol. 2021 Oct;93(10):5768-5776. doi: 10.1002/jmv.27105. Epub 2021 Jun 2.